当前位置: 首页 >> 检索结果
262. TRPC6 inhibition for the treatment of focal segmental glomerulosclerosis: a randomised, placebo-controlled, phase 2 trial of BI 764198.
作者: Howard Trachtman.;Matthias Kretzler.;Loreto Gesualdo.;Nicholas Cross.;Biruh Workeneh.;Jessica Kaufeld.;Björn Meijers.;Zhiming Ye.;Qinkai Chen.;Vimal K Derebail.;Monica Suet Ying Ng.;Bo Ji.;Maximilian T Lobmeyer.;Silke Retlich.;Fabia T Licarião Rocha.;Srinivasa Prasad.;Nima Soleymanlou.
来源: Lancet. 2026年407卷10528期587-598页
In focal segmental glomerulosclerosis (FSGS), transient receptor potential cation channel, subfamily C, member 6 (TRPC6) overactivity might cause podocyte loss and progressive kidney function decline. This exploratory study assessed the safety and efficacy of a novel once-daily oral selective TRPC6 inhibitor, BI 764198.
279. Surgical fixation versus non-surgical care for children with a displaced medial epicondyle fracture of the elbow (the SCIENCE study): a multicentre, randomised controlled, superiority trial and economic evaluation.
作者: Daniel C Perry.;Juul Achten.;Alex Zimmermann.;Rebecca Kandiyali.;Duncan Appelbe.;James G Wright.;David Ferguson.;Kemble Wang.;Nichola Wilson.;Amy Moscrop.;James Mason.;Daphne Kounali.;Matthew L Costa.; .
来源: Lancet. 2026年407卷10528期577-586页
Displaced medial epicondyle fractures are among the most controversial injuries in children, with increasing trends towards surgical fixation despite little supporting evidence. Approximately half of affected children undergo surgical fixation, while others receive non-surgical care. The SCIENCE trial aimed to determine whether surgical fixation to restore the position of the bone provides superior functional outcomes and is cost-effective compared with non-surgical care.
280. Leprosy.
作者: Nelson Iván Agudelo Higuita.;Charlotte Avanzi.;Andrés F Henao-Martínez.;Tanvi P Honap.;Neema Bendera.;Carlos Franco-Paredes.;Rie R Yotsu.;Mendrika Rakotoarisaona.;Natarajan Manimozhi.;John S Spencer.
来源: Lancet. 2026年407卷10530期805-819页
Leprosy, also known as Hansen's disease, is a curable granulomatous condition caused by Mycobacterium leprae or Mycobacterium lepromatosis, disproportionately affecting impoverished communities across the globe. The bacteria's tropism for dermal histiocytes, endothelial cells, and Schwann cells causes neuronal and dermal damage that often results in disability, permanent disfigurement, stigma, and social exclusion. Despite important achievements in the understanding of the disease, its elimination has been hampered by the scarcity of sensitive diagnostic tools, suboptimal integration and implementation of coordinated and financially stable preventive interventions, persistent stigmatisation, and failure to efficiently and sustainably address the socioeconomic and demographic factors associated with an increased risk of leprosy. In this Seminar, we provide an update on key public health and clinical aspects of the disease.
|